RevenueNet IncomeP/EP/SEBITDividendStocksMarket capitalizationDebtLiabilitiesEquityAAQSEmployeesROEROAROCE
Sino Biopharmaceutical Stock

Sino Biopharmaceutical Stocks 2024

Sino Biopharmaceutical Stocks

18.53 B

Ticker

1177.HK

ISIN

KYG8167W1380

WKN

A0CBDJ

In 2024, Sino Biopharmaceutical had 18.53 B outstanding stocks, a 0% change from the 18.53 B stocks in the previous year.

The Sino Biopharmaceutical Stocks history

YEARNUMBER OF STOCKS (undefined CNY)
2029e18.53
2028e18.53
2027e18.53
2026e18.53
2025e18.53
2024e18.53
202318.53
202219.02
202119.28
202018.8
201918.81
201818.55
201716.68
201616.68
201511.79
201411.12
201311.12
201211.12
201111.14
201010.92
200910.19
200810.19
200710.19
200610.19
20059.94
20049.8

Sino Biopharmaceutical shares outstanding

The number of shares was Sino Biopharmaceutical in 2023 — This indicates how many shares 18.529 B is divided into. Since shareholders are the owners of a company, each share represents a small portion of the company's ownership.

  • 3 years

  • 5 years

  • 10 years

  • 25 Years

  • Max

Number of stocks
Details

Revenue, EBIT and Earnings per share

ⓘ

Revenue Per Share

Revenue per share represents the total revenue Sino Biopharmaceutical earns, divided by the number of outstanding shares. It is a crucial metric as it reflects the company's ability to generate sales and signifies growth and expansion potential. Comparing yearly revenue per share allows investors to analyze the consistency in a company’s earnings and predict future trends.

EBIT Per Share

EBIT per share indicates Sino Biopharmaceutical's earning before interest and taxes, offering insights into operational profitability excluding the effects of capital structure and tax rates. It can be juxtaposed against revenue per share to gauge the efficiency in converting sales into profits. A consistent increase in EBIT per share over the years underscores operational efficiency and profitability.

Income Per Share

Income per share, or earnings per share (EPS), reveals the portion of Sino Biopharmaceutical’s profit allocated to each share of common stock. It’s instrumental in evaluating the profitability and financial health. By comparing it with revenue and EBIT per share, investors discern how effectively a firm translates sales and operational profits into net income.

Expected Values

Expected values are projections of revenue, EBIT, and income per share for forthcoming years. These anticipations, rooted in historical data and market analysis, aid investors in strategizing their investments, evaluating Sino Biopharmaceutical's prospective performance, and estimating future stock prices. However, it’s pivotal to consider market volatilities and uncertainties that can influence these projections.

Sino Biopharmaceutical Aktienanalyse

What does Sino Biopharmaceutical do?

Sino Biopharmaceutical Ltd is a leading biopharmaceutical company in China that focuses on research, development, production, and distribution of medications. The company is headquartered in Hong Kong and is listed on the Hong Kong Stock Exchange. The company was founded in 2000 by Dr. Tse Ping, an experienced entrepreneur in the chemical industry. The goal was to develop innovative medications that could improve people's health and lives. Since then, Sino Biopharmaceutical has become a major player in the pharmaceutical industry. Sino Biopharmaceutical's business model is based on three pillars: generics, innovative medications, and contract manufacturing. The company specializes in the development and production of generics to make affordable, high-quality medications accessible to the masses. At the same time, the company also invests in research and development of innovative medications for rare and serious diseases. Additionally, Sino Biopharmaceutical also offers contract manufacturing services to other companies. Sino Biopharmaceutical operates in four divisions: pharmaceutical manufacturing, research and development of biopharmaceutical medications, contract manufacturing, and sales and marketing activities. Pharmaceutical manufacturing includes the production of generics as well as the manufacturing of medications for specific indications. Research and development of biopharmaceutical medications focuses on the development of therapies for severe and rare diseases. Contract manufacturing involves the manufacturing process from raw material sourcing to packaging medications for other companies. Sales and marketing activities involve positioning and promoting Sino Biopharmaceutical's products in the market. Some of Sino Biopharmaceutical's well-known products include Hengrui Medicine, an anticancer medication used to treat cancer; Yigu, a medication for liver diseases; and Tongbi, a medication for osteoporosis. Sino Biopharmaceutical has a strong presence in the Chinese market, as well as the international market. The company exports its products to over 60 countries worldwide. Sino Biopharmaceutical has also become a key partner for international companies and regularly collaborates with other pharmaceutical corporations to expand their expertise in product development and manufacturing. In summary, Sino Biopharmaceutical Ltd is a major player in the pharmaceutical industry that specializes in the development and production of generics and innovative medications. There is also a focus on contract manufacturing of medications for other companies. The company has a strong presence in the Chinese market and exports its products to over 60 countries. Sino Biopharmaceutical ist eines der beliebtesten Unternehmen auf Eulerpool.com.

Stocks Details

Evaluating Sino Biopharmaceutical's Shares Outstanding

Sino Biopharmaceutical's shares outstanding refer to the total number of shares that are currently held by all its shareholders, including institutional investors and restricted shares held by the company’s officers and insiders. The number of shares outstanding is crucial in determining the company's market capitalization and is used by investors to assess the company’s size, financial health, and investment potential.

Year-to-Year Comparison

Tracking the changes in Sino Biopharmaceutical’s shares outstanding over the years can provide investors with insights into the company's financial strategies and market valuation. An increase in shares outstanding can result from actions like issuing new shares, while a decrease can result from buybacks.

Impact on Investments

For investors, understanding Sino Biopharmaceutical’s shares outstanding is essential for evaluating its earnings per share (EPS) and market valuation. A change in the number of shares outstanding can impact the EPS, which is a significant driver of stock prices and investor decisions.

Interpreting Changes in Shares Outstanding

Variances in Sino Biopharmaceutical’s shares outstanding can signal shifts in the company’s financial strategy. An increase may dilute the EPS and share value, indicating potential fundraising or acquisitions. Conversely, a decrease, often due to share buybacks, can enhance share value and indicate the company’s confidence in its financial performance.

Frequently Asked Questions about Sino Biopharmaceutical stock

How many stocks are there of Sino Biopharmaceutical?

The current number of stocks of Sino Biopharmaceutical is 18.53 B undefined.

What does Number of Shares / OutstandingShares mean?

The outstanding shares (or issued shares) of Sino Biopharmaceutical are the total number of shares issued and actively held by shareholders - both external investors and company insiders. However, these must be actual shares. may grant stock options to executives that can be converted into shares.

How has the number of shares of Sino Biopharmaceutical evolved in recent years?

The number of shares of Sino Biopharmaceutical has increased by 0% gestiegen compared to last year.

What does the number of shares mean for investors?

The number of shares outstanding is used to calculate key metrics such as a company's market capitalization, earnings per share (EPS), and cash flow per share (CFPS). The number of outstanding shares of a company is not static and can fluctuate greatly over time.

Why does the number of stocks fluctuate?

There are various factors that can lead to a change. Sino Biopharmaceutical as a company can issue new shares, carry out stock splits or reverse splits.

Does the number of shares have an impact on the performance of Sino Biopharmaceutical?

There is no tangible long-term evidence or study that stocks with a certain number of shares (regardless of Mega/Large/Mid/Small Cap) would yield significantly higher returns than others. There are occasional small studies (limited number of stocks, short investment period) that certain classes outperform or have higher risk, but none of them are 1. conclusive (cause-effect is unclear, experiment is not repeatable) or 2. generalizable (generalization is not possible due to small sample size and time period).

How much dividend does Sino Biopharmaceutical pay?

Over the past 12 months, Sino Biopharmaceutical paid a dividend of 0.08 CNY . This corresponds to a dividend yield of about 2.42 %. For the coming 12 months, Sino Biopharmaceutical is expected to pay a dividend of 0.08 CNY.

What is the dividend yield of Sino Biopharmaceutical?

The current dividend yield of Sino Biopharmaceutical is 2.42 %.

When does Sino Biopharmaceutical pay dividends?

Sino Biopharmaceutical pays a quarterly dividend. This is distributed in the months of November, July, October, October.

How secure is the dividend of Sino Biopharmaceutical?

Sino Biopharmaceutical paid dividends every year for the past 26 years.

What is the dividend of Sino Biopharmaceutical?

For the upcoming 12 months, dividends amounting to 0.08 CNY are expected. This corresponds to a dividend yield of 2.52 %.

In which sector is Sino Biopharmaceutical located?

Sino Biopharmaceutical is assigned to the 'Health' sector.

Wann musste ich die Aktien von Sino Biopharmaceutical kaufen, um die vorherige Dividende zu erhalten?

To receive the latest dividend of Sino Biopharmaceutical from 10/4/2024 amounting to 0 CNY, you needed to have the stock in your portfolio before the ex-date on 9/12/2024.

When did Sino Biopharmaceutical pay the last dividend?

The last dividend was paid out on 10/4/2024.

What was the dividend of Sino Biopharmaceutical in the year 2023?

In the year 2023, Sino Biopharmaceutical distributed 0.1 CNY as dividends.

In which currency does Sino Biopharmaceutical pay out the dividend?

The dividends of Sino Biopharmaceutical are distributed in CNY.

Stock savings plans offer an attractive way for investors to build wealth over the long term. One of the main advantages is the so-called cost-average effect: by regularly investing a fixed amount in stocks or stock funds, you automatically buy more shares when prices are low, and fewer when they are high. This can lead to a more favorable average price per share over time. In addition, stock savings plans allow small investors access to expensive stocks, as they can participate with small amounts. Regular investment also promotes a disciplined investment strategy and helps to avoid emotional decisions, such as impulsive buying or selling. Furthermore, investors benefit from the potential appreciation of the stocks as well as from dividend distributions, which can be reinvested, enhancing the compounding effect and thus the growth of the invested capital.

Andere Kennzahlen von Sino Biopharmaceutical

Our stock analysis for Sino Biopharmaceutical Revenue stock includes important financial indicators such as revenue, profit, P/E ratio, P/S ratio, EBIT, as well as information on dividends. We also assess aspects such as stocks, market capitalization, debt, equity, and liabilities of Sino Biopharmaceutical Revenue. If you are looking for more detailed information on these topics, we offer comprehensive analyses on our subpages.